Improving the treatment paradigm for non-Hodgkin’s lymphoma with bortezomib


https://doi.org/10.4081/hmr.v2i7.409
Vol. 2 No. 7: New Insights in Hematology, Venice (Italy), May 14-17, 2006
Published: June 8, 2009
Abstract Views: 152
PDF: 107
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Targeting of the ubiquitin proteasome pathway has proven to be a valid and efficacious approach for the treatment of several hematologic malignancies, especially multiple myeloma and select non-Hodgkin's lymphoma (NHL) sub-types. To date, several ongoing phase II clinical studies have independently and clearly documented the activity of bortezomib in select sub-types of NHL. What has emerged from the available data is that there may be significant differences among the different sub-types of lymphoma with regard to their sensitivity of proteasome inhibition and the kinetics of the response.

Supporting Agencies


Zinzani, P. (2009). Improving the treatment paradigm for non-Hodgkin’s lymphoma with bortezomib. Hematology Meeting Reports (formerly Haematologica Reports), 2(7). https://doi.org/10.4081/hmr.v2i7.409
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC